Citrix has grown to a $3 billion company driven by approximately fifty acquisitions over the past decade since it went public, enjoying a comfortable 14% CAGR. Why did their senior vice president tell the January 14th Boston breakfast meeting of … Continue reading
Stephen Honig
Moving into the proxy season, what are the hottest board topics this year? Disclosure of corporate political contributions, the impact of enhanced SEC disclosure requirements on executive compensation, heightened audit committee responsibility, and board responsiveness to socially motivated activist shareholders, … Continue reading
I generally avoid politics; people have their own views and do not need mine. I try to stick to things I know a little about: law and occasionally the Boston Red Sox. (I do better on predicting the former.) But … Continue reading
Last week the SEC issued a staff report seeking reaction to proposed amendments to the definition of an “accredited investor.” Regulation D is the most relied-upon exemption from SEC (and typically State) registration requirements for the sale of securities, and … Continue reading
The SEC has been entertaining, for several years, a rule requiring reporting companies to disclose political contributions. Yesterday, a compromise budget bill was announced by Speaker Ryan which includes a rider barring the SEC from finalizing, issuing or implementing any … Continue reading
Dealing with the FDA today is getting slightly easier, but it is nothing to write home about. Agency plans will attempt to improve the regulatory experience; success remains to be demonstrated. Presentations by a research firm and by the Regional … Continue reading
Where is health care going in the United States? Well, no big surprises: it is costing more, is on an upwards cost trend given demographics (e.g. we are getting older as a population), and it is harder to get reimbursement. … Continue reading
At the December 9 symposium on FDA issues for medical device companies sponsored in Waltham by MassMEDIC (the association of device manufacturers), legislation passed by the House of Representatives that would greatly assist the industry was outlined, for the benefit … Continue reading
Current literature is full of warnings about individual liability of directors when corporations violate governmental laws or regulations. I suggest that the practical risk for directors is minimal. The United States Attorney General’s Office is out to emphasize that individuals … Continue reading
A November 13 presentation at the Boston offices of DuaneMorris, by Japanese pharma giant Takeda, addressed to a group of life science and healthcare investors, contained stark facts concerning the cost and difficulty of creating new, significant drugs outside the … Continue reading